Phase 2 and phase 3 trials have also indicated that orforglipron, an oral, non-peptide GLP-1 receptor agonist, is associated with weight loss and improvement in cardiometabolic parameters in adults with obesity or in those with overweight status and at least one weight-related comorbidity, in the absence of diabetes [100,101]. This evidence concerns the gene GLP1R and Obesity.